东富龙收盘下跌1.07%，滚动市盈率61.34倍，总市值91.75亿元

Group 1 - The core business of Dongfulong Technology Group Co., Ltd. is to provide pharmaceutical companies worldwide with pharmaceutical processes, core equipment, and overall system engineering solutions [1] - The company's main products include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] - As of the first quarter of 2025, Dongfulong reported a revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, and a net profit of 20.1326 million yuan, a year-on-year decrease of 68.87%, with a gross profit margin of 24.45% [1] Group 2 - Dongfulong's current price-to-earnings (PE) ratio is 61.34, compared to the industry average of 49.26 and the industry median of 36.71, ranking 94th in the industry [2] - The total market capitalization of Dongfulong is 9.175 billion yuan [2] - As of the first quarter of 2025, seven institutions hold shares in Dongfulong, with a total holding of 89.388 million shares valued at 1.153 billion yuan [1]